{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T07:33:05Z","timestamp":1793345585215,"version":"4.5.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100013806","name":"Shenyang Pharmaceutical University","doi-asserted-by":"crossref","award":["ZQN2015023"],"award-info":[{"award-number":["ZQN2015023"]}],"id":[{"id":"10.13039\/501100013806","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.ejmech.2018.01.081","type":"journal-article","created":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T15:19:53Z","timestamp":1517498393000},"page":"460-470","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Design, synthesis and biological evaluation of novel 4-aminoquinazolines as dual target inhibitors of EGFR-PI3K\u03b1"],"prefix":"10.1016","volume":"146","author":[{"given":"Huai-Wei","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Long","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan-Dan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan-Dan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao-Meng","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9074-2467","authenticated-orcid":false,"given":"Shao-Jiang","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Rui","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2018.01.081_bib1","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1016\/j.bmc.2010.04.046","article-title":"Design and synthesis of novel Gefitinib analogues with improved anti-tumor activity","volume":"18","author":"Wu","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.01.081_bib2","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.ejmech.2016.09.039","article-title":"Design and discovery of 4-anilinoquinazoline-urea derivatives as dual TK inhibitors of EGFR and VEGFR-2","volume":"125","author":"Zhang","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.01.081_bib3","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signalling network","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2018.01.081_bib4","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1002\/cncr.22133","article-title":"Clinical implications of the mechanism of epidermal growth factor receptor inhibitors","volume":"107","author":"Marshall","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.ejmech.2018.01.081_bib5","doi-asserted-by":"crossref","first-page":"5268","DOI":"10.1158\/1078-0432.CCR-05-1554","article-title":"The epidermal growth factor receptor pathway: a model for targeted therapy","volume":"12","author":"Scaltriti","year":"2006","journal-title":"Clin. Canc. Res. Official J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.ejmech.2018.01.081_bib6","first-page":"7184","article-title":"The tyrosine kinase inhibitor ZD1839 (\"Iressa\") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells","volume":"61","author":"Moasser","year":"2001","journal-title":"Canc. Res."},{"key":"10.1016\/j.ejmech.2018.01.081_bib7","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1358\/dot.2006.42.7.985637","article-title":"Lapatinib: a novel EGFR\/HER2 tyrosine kinase inhibitor for cancer","volume":"42","author":"Johnston","year":"2006","journal-title":"Drugs Today"},{"key":"10.1016\/j.ejmech.2018.01.081_bib8","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1634\/theoncologist.10-7-461","article-title":"FDA drug approval summary: erlotinib (Tarceva) tablets","volume":"10","author":"Cohen","year":"2005","journal-title":"Oncol"},{"key":"10.1016\/j.ejmech.2018.01.081_bib9","first-page":"7284","article-title":"ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases","volume":"62","author":"Carlomagno","year":"2002","journal-title":"Canc. Res."},{"key":"10.1016\/j.ejmech.2018.01.081_bib10","first-page":"1336","article-title":"BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors","volume":"9","author":"Minkovsky","year":"2008","journal-title":"Curr. Opin. Invest. Drugs"},{"key":"10.1016\/j.ejmech.2018.01.081_bib11","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.lungcan.2011.10.023","article-title":"Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies","volume":"76","author":"Tan","year":"2012","journal-title":"Lung Canc."},{"key":"10.1016\/j.ejmech.2018.01.081_bib12","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/nrg1879","article-title":"The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism","volume":"7","author":"Engelman","year":"2006","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ejmech.2018.01.081_bib13","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0955-0674(99)80029-5","article-title":"Signalling through phosphoinositide 3-kinases: the lipids take centre stage","volume":"11","author":"Leevers","year":"1999","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.ejmech.2018.01.081_bib14","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrd2926","article-title":"Targeting the phosphoinositide 3-kinase pathway in cancer","volume":"8","author":"Liu","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2018.01.081_bib15","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1006\/geno.1994.1655","article-title":"Molecular cloning, cDNA sequence, and chromosomal localization of the human phosphatidylinositol 3-kinase p110\u03b1 (PIK3CA) gene","volume":"24","author":"Volinia","year":"1994","journal-title":"Genomics"},{"key":"10.1016\/j.ejmech.2018.01.081_bib16","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.ejmech.2016.01.012","article-title":"PI3K\/Akt\/mTOR and Ras\/Raf\/MEK\/ERK signaling pathways inhibitors as anticancer agents: structural and pharmacological perspectives","volume":"109","author":"Asati","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.01.081_bib17","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s00280-013-2121-1","article-title":"PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types","volume":"71","author":"Britten","year":"2013","journal-title":"Canc. Chemother. Pharmacol."},{"key":"10.1016\/j.ejmech.2018.01.081_bib18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1021\/ml900028r","article-title":"Discovery of GSK2126458, a highly potent inhibitor of PI3K and the mammalian target of rapamycin","volume":"1","author":"Knight","year":"2010","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2018.01.081_bib19","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1158\/1535-7163.MCT-08-0017","article-title":"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase\/mammalian target of rapamycin inhibitor with potent in\u00a0vivo antitumor activity","volume":"7","author":"Maira","year":"2008","journal-title":"Mol. Canc. Therapeut."},{"key":"10.1016\/j.ejmech.2018.01.081_bib20","doi-asserted-by":"crossref","first-page":"4367","DOI":"10.1039\/c3ob40368h","article-title":"Novel 5-anilinoquinazoline-8-nitro derivatives as inhibitors of VEGFR-2 tyrosine kinase: synthesis, biological evaluation and molecular docking","volume":"11","author":"Xi","year":"2013","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2018.01.081_bib21","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.ejmech.2016.07.006","article-title":"6-Aryl substituted 4-(4-cyanomethyl) phenylamino quinazolines as a new class of isoform-selective PI3K-alpha inhibitors","volume":"122","author":"Yadav","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.01.081_bib22","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1016\/j.bmcl.2017.03.020","article-title":"Design and synthesis of novel 6-aryl substituted 4-anilinequinazoline derivatives as potential PI3K\u03b4 inhibitors","volume":"27","author":"Xin","year":"2017","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2018.01.081_bib23","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1021\/acsmedchemlett.6b00119","article-title":"Discovery and pharmacological characterization of novel quinazoline-based PI3K delta-selective inhibitors","volume":"7","author":"Hoegenauer","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2018.01.081_bib24","unstructured":"Y. Yosaatmadja, C.J. Squire, M. Mckeage, J.U. Flanagan, 1.85 angstrom structure of EGFR kinase domain with gefitinib."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523418301004?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523418301004?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T22:58:14Z","timestamp":1603753094000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523418301004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":24,"alternative-id":["S0223523418301004"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2018.01.081","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis and biological evaluation of novel 4-aminoquinazolines as dual target inhibitors of EGFR-PI3K\u03b1","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2018.01.081","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}